By Health In Five Writer
BDR Pharmaceuticals International has announced the launch of Dalbonova Injection for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms. This drug will be available as a 500 mg injection.
According to the latest data from the World Health Organization (WHO), in 2023 there were an estimated 11.5 million cases of Acute bacterial skin and skin structure infections (ABSSSI) in India. This represents a 15% increase in the number of cases from 2022. The male-to-female ratio for ABSSSI in India is 1.2:1. This means that men are about 20% more likely to develop ABSSSI than women. Children under the age of five and people over the age of 65 throughout India have the highest incidence of ABSSSI. The incidence of ABSSSI varies by area in India as well, with Gujarat, Rajasthan, and Uttar Pradesh, to mention a few, having the highest rates. Certain population groups in India, such as those with diabetes, HIV/AIDS, and poverty, bear a disproportionately high burden of ABSSSI.
Raheel Shah, Director of BDR Pharmaceuticals said, “Dalbonova Injection is set to provide significant benefits to adult and pediatric patients suffering from ABSSSI. With its innovative approach, BDR Pharmaceuticals aims to enhance patient care and accessibility while making the treatment more affordable for Indian patients. This advanced treatment will not only save valuable time but also reduce the overall cost burden associated with traditional treatment approaches.”
“India is ensuring that patients receive the finest care possible by funding cutting-edge research, encouraging partnerships, and consistently enhancing the nation’s medical infrastructure. It is also significantly time and cost savings. With this BDR aims to introduce innovative medicines first time in India in Anti-Infective segment and also make them affordable for Indian patients”, said Shah